SCHEMBL11944082

SCHEMBL11944082

CCOCCOc1c(N2CCN(S(=O)(=O)c3cc(OC)ccc3OC)CC2)cnn(-c2cccc(Cl)c2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ USP2 O75604 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ KMT2A Q03164 2/20 0.49
▸ MAPT P10636 5/20 0.49
▸ RECQL P46063 1/20 0.49
▸ NPBWR1 P48145 2/20 0.47
▸ MCHR1 Q99705 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PPARG P37231 1/20 0.47
▸ NCOA2 Q15596 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ NCOA3 Q9Y6Q9 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944081 0.95 NPBWR1 (0.48) LMNAALDH1A1L3MBTL1USP2HTT
SCHEMBL11944079 0.90 POLB (0.57) LMNAALDH1A1HTTMAPTNPBWR1
SCHEMBL11945213 0.89 POLB (0.53) LMNAALDH1A1USP2HTTKMT2A
SCHEMBL11945071 0.85 ALDH1A1 (0.54) LMNAALDH1A1KMT2AMAPTNPBWR1
SCHEMBL11943992 0.85 POLB (0.58) LMNAALDH1A1HTTKMT2AMAPT
SCHEMBL11944108 0.85 KMT2A (0.51) LMNAALDH1A1L3MBTL1USP2HTT
SCHEMBL11945595 0.83 MAPT (0.49) LMNAALDH1A1MAPTNPBWR1MCHR1
SCHEMBL11945102 0.83 POLB (0.54) LMNAALDH1A1KMT2AMAPTNPBWR1
SCHEMBL11944078 0.83 POLB (0.59) LMNAALDH1A1L3MBTL1HTTKMT2A
SCHEMBL11945072 0.83 MAPT (0.51) LMNAALDH1A1KMT2AMAPTNPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LMNA 929/4885ALDH1A1 2437/4885L3MBTL1 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback